Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan

Clinical Microbiology and Infection

Volumn 12, Issue 3, 2006, Pages 296-298

  Hsueh, P R ^a   Shyr, J M ^b   Wu, J J ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Antibiotic consumption; Haemophilus influenzae; Macrolides; Resistance; Streptococcus spp.

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG USE; HAEMOPHILUS INFLUENZAE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TAIWAN;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 33644894215     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01348.x     Document Type: Article

References (15)

1. Hsueh PR, Liu CY, Luh KT. Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis 2002; 8: 132-137.
2. Hsueh PR, Chen HM, Huang AH, Wu JJ. Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan. Antimicrob Agents Chemother 1995; 39: 2239-2242.
3. Hsueh PR, Liu YC, Shyr JM et al. Multicenter surveillance of antimicrobial resistance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan during the 1998-1999 respiratory season. Antimicrob Agents Chemother 2000; 44: 1342-1345.
4. Hsueh PR, Shyr JM, Wu JJ. Decreased erythromycin use after antimicrobial reimbursement restriction for undocumented bacterial upper respiratory tract infections significantly reduced erythromycin resistance in Streptococcus pyogenes in Taiwan. Clin Infect Dis 2005; 15: 903-905.
5. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 8th edn. Approved standard M2-A8. Wayne, PA: NCCLS, 2003.
6. Hsueh PR, Teng LJ, Lee NL et al. Extremely high proportion and substantial upsurge in incidence of erythromycin-resistant M phenotype in Streptococcus pyogenes but not in Streptococcus pneumoniae isolates collected over a 15-year period in Taiwan. Microb Drug Resist 2002; 8: 27-33.
7. Seppala H, Klaukka T, Vupio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 491-492.
8. Bergman M, Huikko S, Pihlajamaki M et al. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis 2004; 38: 1251-1256.
9. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346: 1200-1206.
10. Yan JJ, Wu HM, Huang AH, Fu HM, Lee CT, Wu JJ. Prevalence of polyclonal mefA -containing isolates among erythromycin-resistant group A streptococci in Southern Taiwan. J Clin Microbiol 2000; 38: 2475-2479.
11. Hsueh PR, Teng LJ, Wu TL et al. Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART Program 2001 data. Antimicrob Agents Chemother 2003; 47: 2145-2151.
12. Hsueh PR, Luh KT. Antimicrobial resistance in Streptococcus pneumoniae, Taiwan. Emerg Infect Dis 2002; 8: 1487-1491.
13. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 2005; 11: 851-858.
14. Doern GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: Have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41: 139-148.
15. Ho M, Hsiung CA, Yu HT, Chi CL, Chang HJ. Changes before and after a policy to restrict antimicrobial usage in upper respiratory tract infections in Taiwan. Int J Antimicrob Agents 2004; 23: 438-445.